



DIAGNÓSTICOS DA AMÉRICA S.A.

Publicly-held Company

CNPJ/ME 61.486.650/0001-83

NIRE 35.300.172.507

NOTICE TO THE MARKET

Laboratório Lustosa Acquisition is Completed

DIAGNÓSTICOS DA AMÉRICA S.A. ("Dasa" or the "Company") (B3: DASA3), in continuation of notice to the market released by the Company on June 1, 2022, informs its shareholders and the market in general that, considering the approval by the Brazilian Antitrust Authority (CADE) and the compliance with conditions to materialize the transaction, on this date, completed the 100% acquisition of quotas representing the capital stock ("Acquisition") of **PATOLOGIA CLÍNICA DR. GERALDO LUSTOSA CABRAL LTDA.** ("Laboratório Lustosa" or "Entity").

Laboratório Lustosa was founded in 1958 by a clinical pathologist, Dr. Geraldo Lustosa Cabral, which relies on twenty-six (26) units in the city of Belo Horizonte and the metropolitan region. Currently, the Entity provides imaging exams, laboratory tests, and vaccines services, and it relies on a genomic medicine sector with specialized and unique clinical services. In 2021, Laboratório Lustosa won Level 3 accreditation from the National Accreditation Organization (ONA), equivalent to the health management top excellence.

This Acquisition bolsters Dasa's presence in the Belo Horizonte region, Brazil's third largest market, wherein the Company currently has sixty-seven (67) laboratory units of brands under Grupo São Marcos, present in eleven (11) cities of Belo Horizonte's metropolitan region.

Barueri/SP, October 7, 2022.

Glauco Desiderio

Investor Relations Officer